- DTX-301
- SEL-313
- SHP-641
- PRX-OTC
- Other
Ornithine Transcarbamylase Deficiency Market size was valued at USD 896.6 million in the 2029 market and growing at a CAGR of 3.4% from 2029. Ornithine transcarbamylase deficiency is a hereditary condition that causes ammonia to build up in the blood. It is recognised by the absence of the enzyme ornithine transcarbamylase, which can be full or partial (OTC). The enzyme ornithine transcarbamylase (OTC) is required for the breakdown and elimination of nitrogen in the body. The absence of the OTC enzyme results in an excessive buildup of nitrogen in the blood in the form of ammonia. The most prevalent urea-cycle abnormality is OTC deficiency, which affects one in every 40,000 babies. OTC is caused by a mutation on the X-chromosome. As a result, most women are carriers, whereas their boys who have the gene are affected. Progressive lethargy, vomiting, reluctance to eat, and unconsciousness are all indications of OTC deficiency. Nitrogen scavenging agents can help with this deficit. It is possible to develop an OTC deficit at any age. Males are more commonly affected by this neonatal-onset illness, while females are extremely rare. Certain framework which have to be put on for the production of drugs because there is no FDA (Food and Drug Administration) approved drug that exists for this urea cycle disorder which is considered to be the biggest opportunity for global Ornithine-Transcarbamylase. Market players have witnessed strategic collaboration and acquisition to expand their product portfolio and strengthen their position in the market to enhance the revenue of the company. In Dec 2018- The Food and Drug Administration (FDA) expanded the approval of Ravicti (glycerol phenylbutyrate; Horizon Pharma) a nitrogen-binding agent, which is indicated for the chronic management of urea cycle disorders (UCDs) in adults and children. In April 2020- The San Diego biotech announced it had received the FDA’s permission to enter into the clinic with ARCT-810, an investigational treatment for Ornithine Transcarbamylase (OTC) deficiency.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Certain framework which have to be put on for the production of drug because there is no FDA (Food and Drug Administration) approved drug which exists for this urea cycle disorder which is consider to be a biggest opportunity for global Ornithine-Transcarbamylase. It is noticed that the global ornithine-transcarbamylase deficiency market is influenced mainly by increase in the number of people with genetic mutation on X-chromosome. The most effected population is males when compared to the overall population. Most of the treatment cost are out pocket which a normal individual can afford hence government are providing intense funding program to eradicate the Ornithine-Transcarbamylase deficiency. Products include Buphenyl, Ravicti, Ammonul, dietary supplements, and others. This is a life-threatening disorder, which needs extra attention as number of vulnerable people increase during the COVID-19 pandemic because certain medicine ARCT-810 is showing an impressive result on that segment of population. Hence a significant growth can be observed
The ornithine-transcarbamylase deficiency market size was valued at USD 896.6 million in 2022
Lucane Pharma SA, PhaseRx lnc, Promethera Biosciences SA, Selecta Bioscience Inc, Translate bio Inc, Ultragenyx pharmaceuticals, Unicyte AG, Ucyclyd pharma, Horizon Therapeutics plc
The ornithine transcarbamylase deficiency market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Ornithine Transcarbamylase Deficiency Market Introduction |
2.1.Global Ornithine Transcarbamylase Deficiency Market - Taxonomy |
2.2.Global Ornithine Transcarbamylase Deficiency Market - Definitions |
2.2.1.Product Type |
2.2.2.Geography |
2.2.3.Geography |
2.2.4.Region |
3. Global Ornithine Transcarbamylase Deficiency Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Ornithine Transcarbamylase Deficiency Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Ornithine Transcarbamylase Deficiency Market By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. DTX-301 |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. SEL-313 |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. SHP-641 |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. PRX-OTC |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Other |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Global Ornithine Transcarbamylase Deficiency Market By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital Pharmacy, |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacy |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Online Pharmacy |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Ornithine Transcarbamylase Deficiency Market By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Asia Pacific |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Europe |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Ornithine Transcarbamylase Deficiency Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.DTX-301 |
9.1.2.SEL-313 |
9.1.3.SHP-641 |
9.1.4.PRX-OTC |
9.1.5.Other |
9.2. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacy, |
9.2.2.Retail Pharmacy |
9.2.3.Online Pharmacy |
9.3. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.North America |
9.3.2.Asia Pacific |
9.3.3.Europe |
9.3.4.Latin America |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Ornithine Transcarbamylase Deficiency Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.DTX-301 |
10.1.2.SEL-313 |
10.1.3.SHP-641 |
10.1.4.PRX-OTC |
10.1.5.Other |
10.2. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacy, |
10.2.2.Retail Pharmacy |
10.2.3.Online Pharmacy |
10.3. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.North America |
10.3.2.Asia Pacific |
10.3.3.Europe |
10.3.4.Latin America |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.DTX-301 |
11.1.2.SEL-313 |
11.1.3.SHP-641 |
11.1.4.PRX-OTC |
11.1.5.Other |
11.2. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacy, |
11.2.2.Retail Pharmacy |
11.2.3.Online Pharmacy |
11.3. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.North America |
11.3.2.Asia Pacific |
11.3.3.Europe |
11.3.4.Latin America |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.DTX-301 |
12.1.2.SEL-313 |
12.1.3.SHP-641 |
12.1.4.PRX-OTC |
12.1.5.Other |
12.2. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacy, |
12.2.2.Retail Pharmacy |
12.2.3.Online Pharmacy |
12.3. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.North America |
12.3.2.Asia Pacific |
12.3.3.Europe |
12.3.4.Latin America |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.DTX-301 |
13.1.2.SEL-313 |
13.1.3.SHP-641 |
13.1.4.PRX-OTC |
13.1.5.Other |
13.2. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Hospital Pharmacy, |
13.2.2.Retail Pharmacy |
13.2.3.Online Pharmacy |
13.3. Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.North America |
13.3.2.Asia Pacific |
13.3.3.Europe |
13.3.4.Latin America |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Lucane Pharma SA |
14.2.2.PhaseRx lnc |
14.2.3.Promethera Biosciences SA |
14.2.4.Selecta Bioscience Inc |
14.2.5.Translate bio Inc |
14.2.6.Ultragenyx pharmaceuticals |
14.2.7.Unicyte AG |
14.2.8.Ucyclyd pharma |
14.2.9.Horizon Therapeutics plc |
14.2.10.OrphanPacific, Inc. |
14.2.11.Altis Endurance LLC |
14.2.12.SEQENS GROUP |
14.2.13.Baush Health Companies, Inc. |
14.2.14.Abbott |
15. Research Methodology |
16. Appendix and Abbreviations |